info@marketresearchfuture.com   đź“ž  +1 (855) 661-4441(US)   đź“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Point of Care Molecular Diagnostics Companies

Driving rapid and accurate diagnostics, Point of Care Molecular Diagnostics companies focus on developing portable testing solutions. Their innovative technologies enable on-the-spot molecular analysis, providing timely and reliable results for infectious diseases and genetic conditions, ultimately improving patient outcomes through targeted interventions.

Point-of-Care Molecular Diagnostics Key Companies

 


Latest Point-of-Care Molecular Diagnostics Companies Update:

QIAGEN N.V. expands its reach in Japan with the launch of its QIAstat-Dx system and a respiratory panel for syndromic testing. This new offering provides rapid and accurate diagnosis of influenza A/B, RSV, and other respiratory pathogens, enhancing timely interventions in a critical region.


Biocartis NV receives CE marking for its Rapid Idylla GeneFusion Panel, enabling faster treatment decisions in lung cancer patients. This innovative test identifies specific gene fusions associated with targeted therapies, allowing for personalized treatment plans.


Roche Diagnostics unveils its Cobas Pulse System in certain countries with CE Mark acceptance. This next-generation platform offers integrated solutions for professional blood glucose management, catering to the growing demand for point-of-care diabetes monitoring.


List of Point-of-Care Molecular Diagnostics Key companies in the market

  • Abbott Laboratories, Inc. (US)

  • Hoffmann-La Roche Ltd (Switzerland)

  • QIAGEN N.V. (Germany)

  • Becton, Dickinson and Company (US)

  • Cepheid (US)

  • altona Diagnostics GmbH (Germany)

  • Siemens Healthineers AG (Germany)

  • Thermo Fisher Scientific, Inc. (US)

  • ELITechGroup (France)

  • Trinity Biotech plc (Ireland)


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.